Gland Pharma block deal: 5.8% equity change hands via multiple block deals; stock down nearly 6%
Gland Pharma share price: At around 9:26 a.m., shares of Gland Pharma traded 5.95 per cent, or Rs 110.7, lower on BSE at 1,751 apiece. The company's market capitalisation stood at Rs 28,857.28 crore at around the same time.
Gland Pharma share price: Shares of Gland Pharma traded nearly 6 per cent lower in Tuesday's (April 9) trade on BSE as 5.8 per cent equity, or 86.6 lakh shares, changed hands via multiple block deals. As per Zee Business research, Nicomac Machinery was likely to sell a 4.4 per cent stake today.
At around 9:26 a.m., shares of Gland Pharma traded 5.95 per cent, or Rs 110.7, lower on BSE at 1,751 apiece. The company's market capitalisation stood at Rs 28,857.28 crore at around the same time. The stock closed 2.83 per cent, Rs 52.6 lower, and settled at Rs 1,807 apiece.
On Saturday, April 6, the company, through a regulatory filing, informed investors that the US Food and Drug Administration (US FDA) had approved Eribulin Mesylate Injection 0.5 mg/ml in a single-dose vial.
"Gland Pharma Limited (Gland or Company), a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product)," the filing read.
The product is expected to be the first generic approval on the market, and the company expects to launch this product in the near term through its marketing partner.
The product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.
The company is co-developing several complex injectables, including this product, with Orbicular Pharmaceutical Technologies Private Limited.
Established in 1978, Hyderabad-based Gland Pharma has grown over the years from a contract manufacturer of small-volume liquid parenteral products to one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
Gland Pharma share price: Past performance
In a year, shares of Gland Pharma have gained over 40 per cent against the Nifty50's rise of over 29 per cent.
Catch the latest stock market updates here. For all other news related to business, politics, tech and auto, visit Zeebiz.com.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
Retirement Planning: SIP+SWP combination; Rs 15,000 monthly SIP for 25 years and then Rs 1,52,000 monthly income for 30 years
Top Gold ETF vs Top Large Cap Mutual Fund 10-year Return Calculator: Which has given higher return on Rs 11 lakh investment; see calculations
Retirement Calculator: 40 years of age, Rs 50,000 monthly expenses; what should be retirement corpus and monthly investment
SBI 444-day FD vs Union Bank of India 333-day FD: Know maturity amount on Rs 4 lakh and Rs 8 lakh investments for general and senior citizens
EPF vs SIP vs PPF Calculator: Rs 12,000 monthly investment for 30 years; which can create highest retirement corpus
Home loan EMI vs Mutual Fund SIP Calculator: Rs 70 lakh home loan EMI for 20 years or SIP equal to EMI for 10 years; which can be easier route to buy home; know maths
04:09 PM IST